Skip to main content

10 Result(s)

within Judith A. Aberg Remove this filter

and

  1. Article

    Open Access

    Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1

    Efficacy and safety of the attachment inhibitor fostemsavir + optimized background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 BRIGHTE trial in heavily treatment-experienced (HTE) adult...

    Judith A. Aberg, Bronagh Shepherd, Marcia Wang… in Infectious Diseases and Therapy (2023)

    Download PDF (855 KB) View Article

  2. Article

    Open Access

    Toward Safer Opioid Prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial

    The 2016 U.S. Centers for Disease Control Opioid Prescribing Guideline (CDC Guideline) is currently being revised amid concern that it may be harmful to people with chronic pain on long-term opioid therapy (CP...

    Gabriela Cedillo, Mary Catherine George… in Addiction Science & Clinical Practice (2022)

    Download PDF (1402 KB) View Article

  3. No Access

    Chapter

    HIV and Dyslipidemia

    With the development of potent and effective antiretroviral therapy (ART), life expectancy for people with HIV (PWH) has increased to the point that HIV is now considered a chronic illness. People with HIV are...

    Carlos D. Malvestutto, Judith A. Aberg in Therapeutic Lipidology (2021)

  4. Article

    Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study

    Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments1. Convalescent plasma, donated by persons who have...

    Sean T. H. Liu, Hung-Mo Lin, Ian Baine, Ania Wajnberg… in Nature Medicine (2020)

    Download PDF (1783 KB) View Article

  5. Article

    An inflammatory cytokine signature predicts COVID-19 severity and survival

    Several studies have revealed that the hyper-inflammatory response induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major cause of disease severity and death. However, predictive bi...

    Diane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang… in Nature Medicine (2020)

    Download PDF (5608 KB) View Article

  6. No Access

    Article

    Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy

    In the current era of available therapy for human immunodeficiency virus (HIV), life expectancy for persons living with HIV (PLWH) nears that of the general population. Atherosclerotic cardiovascular disease (...

    Emma Kaplan-Lewis, Judith A. Aberg, Mikyung Lee in Current HIV/AIDS Reports (2016)

  7. No Access

    Article

    Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332

    Identification of biomarkers and/or mediators of cardiovascular disease (CVD) associated with HIV infection would be of diagnostic and therapeutic value. As soluble receptor for advanced glycation endproducts ...

    Ann Danoff, Michelle A. Kendall, Judith S. Currier, Theodoros Kelesidis… in Inflammation (2016)

  8. No Access

    Article

    HIV Counseling and Testing for Household Members of HIV-Infected Individuals in Africa: Should Prevention Programs Focus on Home-Based Rather than Clinic-Based Outreach?

    Michelle DallaPiazza, Judith A. Aberg in Current HIV/AIDS Reports (2011)

  9. No Access

    Article

    New goals for viral suppression in HIV treatment in even the most experienced of patients

    Stephanie A. Sterling, Judith A. Aberg in Current HIV/AIDS Reports (2009)

  10. No Access

    Article

    Neuropsychiatric Complications of Antiretroviral Therapy

    Neuropsychiatric adverse effects related to potent antiretroviral therapy are among the complications that can lead to poor adherence, treatment interruptions, or change of antiretroviral therapy regimens. For...

    Dr Michelle S. Cespedes, Judith A. Aberg in Drug Safety (2006)